COVID-19 is an emerging, rapidly evolving siituation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

OCCPR: A Leader in Cancer Proteomics and Proteogenomics

The mission of the NCI’s Office of Cancer Clinical Proteomics Research (OCCPR) is to improve prevention, early detection, diagnosis, and treatment of cancer by enhancing the understanding of the molecular mechanisms of cancer, to advance proteome and proteogenome science and technology development through community resources (data and reagents), and to accelerate the translation of molecular findings into the clinic. This is achieved through extramural programs such as the Clinical Proteomic Tumor Analysis Consortium (CPTAC), partnerships with Federal agencies, collaborations with international organizations/institutions, and intramural reference laboratories such as the Antibody Characterization Lab and Clinical Proteomic Characterization Lab.

The International Cancer Proteogenome Consortium

International Cancer Proteogenome Consortium

Learn about ICPC and how the consortium is breaking down silos to advance proteogenomic cancer research worldwide.

News and Announcements

April 4, 2024
Characterizing the Evolution of Glioblastoma

Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis despite advancements in treatment and diagnosis. Tumor recurrence, developing in most patients (>90%), poses a major challenge due to tumor heterogeneity and limited understanding of post-treatment evolution. Previous studies have...
March 29, 2024
Presenting our 2024 CPTAC Meritorious Posters

The Clinical Proteomic Tumor Analysis Consortium (CPTAC) recently held its Scientific Investigator Meeting in Portland, Oregon at the Oregon Health & Science University campus. The meeting featured key scientific and programmatic updates spanning multiple cancer types presented by consortium...
March 20, 2024
Proteomics in Focus: Insights from Dr. Nicole Tignor

The following is the third entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Nicole Tignor, PhD, Assistant Professor at the Icahn School of Medicine at...
February 23, 2024
Proteogenomic Characterization of Small Cell Lung Cancer: A Pathway to Personalized Medicine

Small cell lung cancer (SCLC) is an aggressive form of lung malignancy with historically poor prognoses and limited options for targeted treatment. The low availability of suitable biospecimens has also hampered large molecular characterization efforts.
February 14, 2024
Deciphering the Tumor Microenvironment: A Proteogenomic Pan-Cancer Analysis

The tumor microenvironment (TME) is a complex network which plays a crucial role in cancer progression and treatment responses. In a recently published Pan Cancer analysis, the Clinical Proteomic Tumor Analysis...
January 22, 2024
Advancing Personalized Treatment Strategies for Patients with Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood. AML is known for its heterogeneity, presenting challenges in treatment and predicting patient outcomes.
January 8, 2024
Excellence in Proteomics Research: A Conversation with Jeffrey Whiteaker

The following is the second entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Jeffrey Whitaker, PhD, Director of Proteomics within the Paulovich Lab at...
December 5, 2023
CPTAC Collaboration with Morehouse School Of Medicine Promotes Diversity Of Samples For Proteogenomic Analysis

A new collaboration between the Morehouse School of Medicine (MSM) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) aims to enhance diversity of cancer patients included in proteogenomic studies.
November 27, 2023
Integrating Molecular and Computational Techniques in Biology with Natalie Clark

The following is the first entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss molecular and computational techniques in biology with Natalie Clark, PhD from the Proteomics Platform at the Broad...
October 30, 2023
Sweden’s Lund University and United States National Cancer Institute Sign Extension of MOU for Proteogenomics Cancer Research

The National Cancer Institute (NCI) and Lund University in Sweden are pleased to announce the signing of an extension to their memorandum of understanding (MOU) for proteogenomics cancer research. The MOU, involving NCI’s International Cancer Proteogenome Consortium (ICPC) and Clinical Proteomic...

Pages

more

View all News and Announcements

NIH…Turning Discovery Into Health®